Zimbabwe has rejected a major American health deal worth $367m (272 million pounds) over five years because of the United States' request for confidential data.
This move came to light after a internal memorandum from December was leaked, which showed President Emmerson Mnangagwa deemed the deal was "lopsided".
An official representative later clarified that the US was demanding access to health data for research and commercial gain while was unwilling to guarantee the benefits from future vaccines.
"We are forced to start the difficult and regrettable task of scaling back our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the United States had donated more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for more negotiations to find a deal acceptable to both sides so the country's vital HIV programme can proceed.
Broader Context
This rejection follows a comparable case in neighbouring Kenya, where a high court suspended a similar health funding agreement following concerns were filed about the security of Kenyans' medical information.
After returning to office last year, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
USAID had overseen assistance for the US government, but Trump argued its spending was "inefficient" and his administration was seeking government-to-government deals to enhance openness and responsibility.
According to statements, 16 nations in Africa have to date agreed to similar agreements, representing over $18.3bn of fresh investment.
Details of the Rejected Agreement
This assistance for Zimbabwe would have supported "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this partnership might have yielded significant advantages for the people of Zimbabwe, especially the 1.2 million men, women and children presently on HIV treatment through US-supported programmes," Tremont added.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"Zimbabwe was being asked to surrender its genetic material and health information over an extended period, with no corresponding promise of access to any scientific breakthroughs – like new medicines or tests – that could result from that provided information," Mangwana explained.
"Put simply, our country would provide the raw materials for medical research with no assurance that the final treatments would be available to our people should a future disease outbreak emerge."
National Interest and Global Health
He also noted that the American exit from the global health body and its pursuit of one-on-one deals were undermining structures already set up via the international health agency.
Mangwana cited its Pandemic Benefit-Sharing framework created to manage potential global health emergencies.
"This system is intended to ensure that when a country provides its samples, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised solely by those with the capability to develop them."
The government's concerns regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We are open to further discussions with our US partners on how future collaboration might be arranged in a manner that respects the independence and dignity of both nations."
Health Experts Reaction
A leading public health body stated it acknowledged the official position, but recommended that negotiations need to persist since much of the nation's Aids initiatives depended on external financing.
"In cases where specific concerns arise, including those relating to information security or implementation frameworks, these can frequently be addressed via technical clarification and mutually agreed protections," the group said.
The situation highlights the complex tensions between accepting vital international aid and safeguarding national sovereignty in an increasingly data-driven world.